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Summary  
Background: Immunological tolerance in humans using anti T-cell monoclonal antibodies 
(mAbs) may be hampered by a pro-inflammatory microenvironment. All clinical trials of such 
therapies in rheumatoid arthritis (RA), however, have selected patients with active disease at 
baseline. Concurrent neutralization of inflammation with a TNFα antagonist should 
maximize the potential of anti-T cell mAbs to induce tolerance in RA. 
Aim: To evaluate the safety of combining a TNFα antagonist and CD4 mAb in RA.  
Design: An iterative pilot study focused on the safety of such combination therapy.  
Methods: Eight poor prognosis, seropositive RA patients were treated with combined CD4 
and TNFα blockade. Prolonged CD4 blockade was achieved with a humanised mAb, and 
TNFα blockade with a p55 TNF receptor fusion protein. 
Results: There was a low incidence of classical first-dose reactions to the CD4 mAb, possibly 
reflecting concomitant TNFα blockade. An unusual anaphylactoid reaction was seen, 
however, and one patient developed a probable allergic reaction after several infusions. Skin 
rashes were common, as previously reported with CD4 mAb monotherapy. No serious 
infections were documented during follow-up, despite CD4+ lymphopenia in some patients. 
Most patients appeared to demonstrate improved RA disease control after the study. 17-49 
months after therapy one patient was in remission, one remained off disease modifying anti-
rheumatic drugs (DMARDs), and 5 had stable disease, 3 on previously ineffective doses of 
methotrexate.  
Conclusions: We report, for the first time in man, immunotherapy with a combination of an 
anti-cytokine and an anti-T cell reagent. We witnessed an unusual first-dose reaction but there 
were no significant infectious complications.  
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Introduction 
Anti-cytokine therapies are effective agents for reducing inflammation and preventing joint 
destruction in patients with RA. Current data, however, suggest that long-term treatment will 
be necessary when using these drugs, with the attendant risk of opportunistic infection.1 In 
contrast, data from animal models suggests that the combination of anti-cytokine and anti-T 
cell therapy may provide longer term benefit from brief courses of therapy. Thus, anti-CD4 
therapy was synergistic with TNFα blockade,2 and anti-CD3 therapy provided particularly 
robust responses when combined with anti-TNFα therapy.3 An obvious concern of combining 
biological therapies, however, is that this approach may increase the likelihood of serious side 
effects, particularly infection and, potentially, malignancy. For example, infection was a 
significant problem when TNFα and IL-1 blockade were combined4 and TNFα blockade 
alone carries a significant risk.5, 6 An increased incidence of serious infections was also 
reported when costimulation and cytokine blockade were combined.7 On the other hand, the 
risks of cytokine blockade should be minimized if the duration of therapy could be reduced.  
We have performed a pilot study of TNFα blockade and CD4 monoclonal antibody (mAb) 
therapy in a small cohort of patients with refractory RA. Because the dose and duration of 
treatment that might be needed to gain long-term disease control in man is unknown8 our 
study incorporated pragmatic, iterative and escalating dosing scenarios. Patients received 
between one and twelve weeks of therapy and some patients received repeated treatment. 
Despite the intensive nature of the treatment regimes, there were no examples of severe or 
atypical infections. 
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Patients and Methods 
Patients 
Eight patients with active, seropositive RA were recruited (Table 1), following approval from 
the Local Research Ethics Committee. Seven patients were HLA-DRB1*0101, *0401 or 
*0404 positive and five patients were homozygous for the rheumatoid HLA-DRB1 “shared 
epitope”, which is associated with a poor prognosis.9 Each patient fulfilled the following 
disease activity criteria: >6/28 swollen joints and C-reactive protein >29 mg/L, and in 
addition either early morning stiffness >45 minutes or >6/28 tender joints. A four-week 
washout period from all DMARDs was observed but concomitant stable doses of 
prednisolone (<10mg) and non-steroidal anti-inflammatory drugs (NSAIDs) were allowed. 
No intramuscular or intra-articular steroids were permitted during the washout period or 
treatment phases of the study. Patients were assessed weekly during treatment, and then 2-4 
weekly according to clinical need. Infections and other potential adverse events were recorded 
at each visit using a standard proforma. An ACR20 and ACR-N response was calculated at 
each follow-up visit.10 
 
Therapeutic agents  
The Oxford Therapeutic Antibody Centre supplied the biological agents. The CD4 mAb 
(hIgG1-CD4) was a humanized mAb of IgG1 isotype, capable of mediating antibody-
dependent cell-mediated cytotoxicity in vitro.11 It had previously been administered in a pilot 
study to psoriasis and RA patients wherein brief, 5-day courses resulted in antigen 
modulation, and transient depletion of CD4+ T-cells from peripheral blood.12 The bivalent 
TNF antagonist (TNFr-Ig) was a p55 TNF receptor extracellular domain fused to the hinge, 
CH2 and CH3 domains of human IgG1, and was designed, constructed and produced ‘in-
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house’ (This study was initiated prior to the widespread availability of anti-TNFα drugs). 
TNFr-Ig had not been used to treat RA previously but potently blocked TNFα in vivo.13 
 
Study Protocol  
Pre-clinical data suggested that the achievement of therapeutic tolerance may require mAb-
mediated masking of CD4 antigen on T-cells for a period of 6-12 weeks.8 Therefore our aim 
was to slowly escalate our anti-CD4 dosing regime to one which might safely achieve this 
outcome, simultaneously controlling inflammation by TNFα blockade. We adopted an 
approach in which patients could receive more than one course of therapy. The patients were 
followed weekly and a disease flare was defined as a failure to maintain an ACR20 response 
on two successive weeks. The first 5 patients (group 1, Figure 1) received initial treatment 
comprising a single dose of TNFr-Ig (50 or 100mg) followed by 4 daily infusions of hIgG1-
CD4 (125mg per day) (standard combination therapy, phase 1). They were followed weekly 
and they entered phase II and received a second course of treatment comprising TNFr-Ig 
alone following a disease flare. Phase III (following a second disease flare) comprised another 
course of standard combination therapy. These three phases of the study provided an initial, 
crude comparison of TNFα monotherapy and combination therapy. A third flare was followed 
by a 6 week course of therapy comprising standard combination therapy during week 1 and 
then 5 weekly infusions of 100mg hIgG1-CD4. A minimum CD4+ lymphocyte count of 0.4 x 
109/L (lower limit of normal for the local laboratory) was required to progress through the 
various courses of treatment.  
Three additional patients entered phase V, which was designed to maintain CD4 blockade for 
12 weeks whilst continuously suppressing inflammation with TNFr-Ig. Therapy comprised 
TNFr-Ig (100mg) at weeks 0, 4 and 8 and hIgG1-CD4 (200mg weekly) from weeks 0-11.  
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Lymphocyte subset analysis 
Lymphocyte subtyping (CD3+, CD3+ CD4+, CD3+ CD8+, CD19+ B cells and CD3- CD16+, 
or CD56+ CD16+ NK cells) was performed using flow cytometry. The antibodies used to 
label CD4+ cells recognized non-overlapping CD4 epitopes to hIgG1-CD4, and included 
QS4120 (American Tissue Type Culture Collection) for study 1 and Leu-3a for study 2. 
 
Laboratory monitoring 
Full blood count was measured weekly during therapy, urea and electrolytes and liver 
function tests every 2-4 weeks. Antinuclear antibody was measured monthly and rheumatoid 
factor, anti-double stranded DNA antibodies and anti-cardiolipin antibodies bi-monthly. 
 
Anti-globulin responses 
Anti-globulins to the biological agents were measured using a double capture ELISA as 
previously described.14 In short, ELISA plates were coated with either hIgG1-CD4 or TNFr-Ig 
and blocked according to standard procedures. Following incubation with test serum, plates 
were washed and antiglobulins detected with biotin-labeled hIgG1-CD4 or TNFr-Ig 
respectively.  
 
Skin prick testing 
Test solutions were placed onto the skin and pricked into the dermis using a lancet. A 5mm 
wheal from histamine (1mg/ml, NHS pharmacy supplied) served as a positive control and no 
reaction to normal saline, a negative control. Antibody solutions used were hIgG1-CD4, 
TNFr-Ig, combination of the two, and a human IgG1 anti-CD18 mAb as an isotype control. 
Initial tests used mAb solution at 10µg/ml in normal saline, then 100µg/ml if no reaction and 
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finally 1 mg/ml. The test was terminated (positive reaction) if a wheal of 3mm or greater than 
control was elicited after 10 minutes. 
 
Statistics
A comparison of adverse reactions in this study with a previous study utilizing hIgG1-CD4 
was performed using Fishers Exact Test.
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Results 
Recruitment 
Five patients with active RA were recruited for phases I-IV (Table 1). Four were female, 
mean age was 44 years and all were seropositive. Disease duration ranged from 1 to 8 years 
(median 3), and previous DMARD usage from 1 to 8 drugs (median 3).  Three patients 
completed all four treatment phases. One withdrew between phases II and III for reasons 
unrelated to her RA and a second patient was excluded from phase III due to CD4 
lymphopenia. 
Three additional seropositive, female patients entered phase V (Table 1). Mean age was 48 
years, disease duration 3 to 5.5 years (median 5) and previous DMARDS used 3 or 4 (median 
3). Two completed the 12 week course of treatment but one discontinued at week 9 secondary 
to escalating infusion reactions (see below). 
 
Safety 
Infections. No infections were documented during the treatment period of the study, and no 
serious infections during the follow-up period, which lasted from 17 to 49 months (serious 
infection implied a requirement for parenteral antibiotics or admission to hospital).  
First dose reactions (Table 2). Cytokine release syndromes or ‘first dose reactions’ have been 
associated with the initiation of therapy with a number of therapeutic mAbs, particularly those 
that bind to cells.12, 15, 16 In their most severe form these can be life-threatening.17 The 
classical syndrome occurs 90-120 minutes into the infusion and comprises chills, fever, 
headache and, in severe cases, bronchospasm, chest tightness and hypotension. No reactions 
occurred with the first dose of p55-TNFr-Ig but a mild or moderate severity reaction was seen 
in 2/8 patients treated with hIgG1-CD4 for the first time. All patients in phase I, however, 
experienced an unusual, very early reaction to the first dose of hIgG1-CD4. The reaction 
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occurred within the first 5 minutes of the infusion and comprised flushing, vomiting, chest 
tightness, palpitations and dyspnoea, with transient hypotension additionally occurring in 3 
patients. The symptoms reversed rapidly on stopping the infusion, and did not recur when 
restarted or with subsequent doses. Patients were re-exposed to hIgG1-CD4 during phases III 
and IV (Figure 1). These exposures were preceded by the administration of 10mg parental 
chlorpheniramine and no reactions were seen on these occasions. The same pre-medication 
was administered to patients in phase V (who had not previously been exposed to hIgG1-
CD4), but two of three patients developed early reactions. All of the CD4 mAb solutions had 
undergone batch testing for endotoxin and this was deemed an unlikely cause of these 
reactions. In a previous study using hIgG1-CD4 at a similar dose, 10/11 RA and psoriasis 
patients  experienced a classical first-dose reaction  and  a single patient an atypical reaction 
(P=0.004 and 0.001 for a comparison between these studies).12 
Allergic reaction. A recurrent infusion reaction was seen in two patients in phase V (patients 
F and G, Table 2). Transient flushing was seen with each hIgG1-CD4 infusion in both 
patients. However, patient G developed transient chest tightness on week 8, which was 
additionally associated with hypotension, rigors and fever on week 9 and, as a result of these 
reactions, no further infusions were given. A mild eosinophilia (0.52 x 109/L) also developed 
in this patient, which persisted for 8 weeks, although the eosinophil count remained above 
baseline for 72 weeks (Figure 2). Patient H developed mild facial oedema following the final 
infusion of hIgG1-CD4, which persisted for several days. This patient also developed a 
transient eosinophilia (Figure 2). Because these appeared to be allergic reactions, skin prick 
tests were performed on the three patients from phase V and four of the patients from the 
earlier phases. All mounted a satisfactory reaction to histamine but no reaction to either 
biological agent either alone or in combination, at concentrations up to 1mg/ml. This 
significantly reduced the likelihood of, but did not exclude, the development of IgE 
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antiglobulins. 
Rashes. Maculopapular rashes were seen in 5 patients during therapy, four from phases I-IV 
and one from phase V (Table 2). In 3 cases the rashes were generalized and pruritic, lasting 
for several weeks before clearing. Skin biopsies obtained from 4 of these patients 
demonstrated mild immune cell infiltration, but with no evidence of vasculitis or immune 
complex deposition.  
Lymphocyte depletion (Figure 3). In phase I there was a rapid fall in peripheral blood CD4+ 
lymphocyte count. At week 10, CD4 counts remained lower than baseline in 4 patients, but 
were generally within the normal range, consistent with previous experience using this 
mAb.12, 16 Patient B had a prolonged fall in CD4 count following phase I, and was excluded 
from subsequent treatment phases. No further sustained reduction in the CD4 count occurred 
in patients re-exposed to hIgG1-CD4 in phase III, but there was a further fall in two of three 
patients exposed to six weeks of therapy in phase IV. Prolonged dosing with hIgG1-CD4 in 
phase V also resulted in CD4+ lymphopenia, with slow recovery. There were no consistent 
changes in the CD8, NK cell or B cell populations during any phase of the study.  
Laboratory values. No abnormalities of renal or hepatic function were noted during the 
course of the study. 
Antiglobulin responses. After extensive testing we could not demonstrate an immune 
response against either hIgG1-CD4 or TNFr-Ig, even in the patients with escalating infusion 
reactions.  
Autoantibodies. There was no significant change in rheumatoid factor titer and no patients 
developed new dsDNA or ANAs during our studies. Patients A and E had transient increases 
in IgM, but not IgG, anti-cardiolipin antibodies following the unopposed TNF antagonism in 
phase II. These returned to baseline within 6 months and no further rises were seen during 
subsequent treatment courses. 
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Clinical outcome 
This was not a formal efficacy study, and the number of patients treated was small, but the 
design allowed limited observations to be made. TNFr-Ig provided marked relief of RA 
symptoms in all patients and on each occasion it was administered, with initial improvement 
in the ACR response criteria of 40-93% after one week (data not shown). Pooling all patients, 
irrespective of TNFr-Ig dose, median (range) ACR 20 response duration was  3 (2-10) weeks 
for phase I, 1 (1-3) week for phase II, 5 (1-6) weeks for phase III, and 6 (2-9) weeks for phase 
IV (Figure 1). The shortest response durations corresponded to treatment with TNFr-Ig alone, 
suggestive of synergy between the two biological agents.  
Pharmacokinetic data suggested that 100mg hIgG1-CD4 was probably insufficient to 
maintain coating of CD4+ lymphocytes between weekly doses (Dr N Rapson, personal 
communication). This resulted in the protocol adopted for phase V, during which all 3 
patients achieved an ACR70 response on at least one occasion. One patient has subsequently 
required no further treatment for her RA, except a single dose of intramuscular steroid 
(120mg methylprednisolone) for a minor flare at 56 weeks. The remaining 2 patients flared 
shortly after the end of treatment at weeks 14 and 17, but subsequently responded to 
methotrexate at previously ineffective doses (Table 1). At 18 months all 3 patients had ACR-
N responses of 43-75% (Table 1). 
At 3 years, of the four patients available for follow-up from phases I-IV, one is in remission18 
and 3 have stable disease with improvements of between 60 and 83% from baseline. One of 
these is taking MTX at a previously ineffective dose (Table 1).  
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Discussion 
This is the first report of the use of combination anti-cytokine and anti-T-cell biological 
therapy in man. Our study was prematurely terminated secondary to CD4+ T-cell depletion 
and our conclusions are therefore based on a very small patient cohort albeit with substantial 
follow-up. Consistent with our previous studies of lymphocytotoxic mAb therapy19 we saw 
no infectious complications in the current study. In addition, there have been no serious 
infections during 18 months (phases I-IV) to 3 years (phase V) of routine clinical follow-up.  
First-dose reactions were documented in the majority of patients treated but these differed 
qualitatively and appeared earlier than classical first dose reactions.12, 20-22 The latter are the 
consequence of lymphocyte-bound mAb being cross-linked, via Fcγ Receptors (FcγR), 
leading to cytokine secretion from the lymphocytes themselves, or from the FcγR-bearing 
cells.23, 24 TNF plays a crucial role in symptomatology, along with IL-6 and interferon-gamma 
(IFNγ).25 The prior administration of TNFr-Ig may, therefore, explain the low incidence of 
classical reactions compared to previous experience using hIgG1-CD4.12 More puzzling was 
the regular occurrence of a very early reaction, which was anaphylactoid in nature. Although 
reactions were not seen in phase III, when the same patients received chlorpheniramine pre-
medication, they did occur in phase V (with a new patient cohort) despite similar prophylaxis. 
Reduced reactions in phase III may therefore have reflected tachyphylaxis. Similar reactions 
were not seen with TNFr-Ig alone and rarely with hIgG1-CD4 alone in a previous study.12 It 
is possible that TNFr-Ig sensitized T-cells, with rapid mediator release following subsequent 
binding of hIgG1-CD4. TNF blockade facilitates signaling within RA T-cells,26 lending some 
credence to this hypothesis. 
Two patients in phase V became sensitized to hIgG1-CD4 infusions. In one this led to an 
anaphylactoid reaction, in the other to facial oedema, but both developed peripheral blood 
eosinophilia. We could not detect antiglobulins against either agent despite repeated testing 
Combination Immunotherapy  
13 
and it remains possible that the patients became sensitized to a minor component of the mAb 
preparations. In animals, CD4 mAbs administered at sufficiently high doses induce tolerance 
to themselves.27 Furthermore, although TNFα antagonists can be immunogenic,28,29 this 
outcome should be reduced by concomitant CD4 therapy.30 
Lymphopenia developed following extended dosing with hIgG1-CD4 (Figure 3) whereas 
sustained CD4+ T-cell depletion did not follow a short course of therapy with this mAb.12  
Three of our patients developed generalized and protracted rashes. Histology was non-
specific but did not suggest vasculitis or immune complex deposition, similar to reports with 
several other CD4 mAbs.16, 31, 32 
This was not an efficacy study, but all patients available for long-term follow-up (7 of 8) had 
substantially improved symptoms and signs compared to baseline. One was in disease 
remission, and one no longer required DMARD therapy. Of the remaining 5 patients, three 
were stable on previously ineffective doses of methotrexate. A formal controlled trial would 
obviously be required to substantiate these observations, which hint at some type of disease 
modulation or ‘reprogramming’.8  Immune deviation contributes to immunomodulation in 
animal models of immunotherapy,33, 34 The eosinophilia noted in patients G and H probably 
represented hypersensitivity reactions to a component of therapy, but sustained combination 
therapy may have driven a therapeutically beneficial Th1 to Th2 cytokine switch.  
Several CD4 mAbs, with distinct properties and profiles, have been tested in early phase RA 
clinical trials.35 There was a disappointing lack of observed efficacy compared to pre-clinical 
data from animal models but these studies were performed in the absence of therapeutic 
tolerance biomarkers. RA outcomes rely heavily on markers of inflammation and agents that 
induce therapeutic tolerance may not primarily be anti-inflammatory. Furthermore, anti-
inflammatory and immunosuppressive drugs may even disrupt tolerance mechanisms. In the 
absence of validated tolerance biomarkers, critically important parameters such as drug dose 
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and therapy duration will continue to be chosen pragmatically, as in our study. The ‘wrong’ 
choice may lead to potentially tolerogenic therapies being inappropriately and prematurely 
abandoned.36,37 In contrast, used with a suitable anti-inflammatory regime and with 
appropriate biomarker monitoring, such therapies could yet prove to be potent immune 
modulators in humans.  
In conclusion we report, for the first time, combination therapy in man with anti-cytokine and 
anti-T cell ‘biological’ therapies. We witnessed an unusual first-dose reaction and a high 
incidence of skin rashes, but no infectious complications despite a degree of CD4+ 
lymphopenia. Symptomatic outcomes were encouraging but formal, controlled trials of such 
protocols additionally require the identification and development of appropriate biomarkers 
of immune modulation.37,38  
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Figure Legends. 
Figure 1. Therapeutic strategy in study 1 and ACR20 response duration. In phase I 
patients received 50mg (patients marked with *) or 100mg TNFr-Ig (solid arrow) followed by 
125mg hIgG1-CD4 daily for 4 days (broken arrows). Each patient is represented by a 
different symbol. In phase II, patients received TNFr-Ig monotherapy, at the same dose as in 
phase I. Three patients progressed to phase III and received 100mg TNFr-Ig followed by 
125mg hIgG1-CD4 daily for 4 days. In phase IV, patients received 100mg TNFr-Ig followed 
by 125mg hIgG1-CD4 daily for 4 days, and then weekly infusions of 100mg hIgG1-CD4. 
Patients were required to flare before progressing to a subsequent phase of the study, and to 
maintain a minimum CD4+ lymphocyte count of 0.4 x 109/L. 
 
Figure 2. Eosinophil counts of patients participating in phase V. 
 
Figure 3. CD4+ lymphocyte counts from phases I-V. 
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Figure 1.  Therapeutic strategy in study 1 and ACR20 response duration. 
 
 
 
In phase I patients received 50mg (patients marked with *) or 100mg TNFr-Ig (solid arrow) 
followed by 125mg hIgG1-CD4 daily for 4 days (broken arrows). Each patient is represented 
by a different symbol. In phase II, patients received TNFr-Ig monotherapy, at the same dose 
as in phase I. Three patients progressed to phase III and received 100mg TNFr-Ig followed by 
125mg hIgG1-CD4 daily for 4 days. In phase IV, patients received 100mg TNFr-Ig followed 
by 125mg hIgG1-CD4 daily for 4 days, and then weekly infusions of 100mg hIgG1-CD4. 
Patients were required to flare before progressing to a subsequent phase of the study, and to 
maintain a minimum CD4+ lymphocyte count of 0.4 x 109/L. 
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Figure 2.  Eosinophil counts of patients participating in phase V. 
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Figure 3: CD4+ Lymphocyte counts during phases I-V. 
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Table 1:  Demographic data and outcome at most recent follow-up. 
 
 
Demographic Data  
 
Long-term outcome 
 
Patient 
 
 
 
 
Age 
(years) 
 
Sex 
 
Disease 
Duration 
(years) 
 
 
Previous failed 
DMARDs a 
 
Time 
(months) 
from last 
treatment 
 
% improvement 
in ACR criteria b 
 
Current Therapy 
 
A  
 
41 
 
F 
 
2 
 
S 
 
36 
 
83 
 
Me (20) 
 
B  
 
41 
 
F 
 
8 
 
Au, Az, C, H, Me (10), My, P, S  
 
49 
 
60 
 
Me (10) 
 
C  
 
36 
 
M 
 
1 
C, Me (15), S  36 
 
66 
 
Me (20) + C 
 
D  
 
51 
 
F 
 
4 
 
H, Me (10), P, S  
 
 
 
* 
 
 
E  
 
53 
 
F 
 
3 
 
Me (15), S 
 
36 
 
Remission c 
 
Me (15) + C 
 
F  
 
39 
 
F 
 
3 
 
H, Me (20), S  
 
18 
 
75 
 
Me (15) 
 
G 
 
52 
 
F 
 
5.5 
 
H, Me (10), S  
 
18 
 
49 
 
nil 
 
H 
 
52 
 
F 
 
5 
 
C, H, Me (17.5), S  
 
17 
 
43 
 
Me (15) 
a Au = auranofin, Az = azathioprine C = cyclosporin A, H = hydroxychloroquine, Me = methotrexate (dose in mg), My = myocrisin, P = 
penicillamine, S = sulphasalazine. 
b ACR response criteria:  % improvement in the number of swollen and tender joints with the same % improvement in at least 3 of the following: 
patient's assessment of pain, patient's assessment of disease status, physicians assessment of disease status, C-reactive protein and health 
assessment questionnaire [8]. 
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c Fulfilled ACR remission criteria: 5 of the following requirements must be fulfilled for at least two consecutive months: duration of morning 
stiffness not exceeding 15 minutes, no fatigue, no joint pain (by history), no joint tenderness or pain on motion, no soft tissue swelling in joints 
or tendon sheaths, normal acute phase response [15].  
* This patient was lost to follow up and no long-term data is available. 
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Table 2.      Adverse effects recorded during and subsequent to therapy. 
Trial Patient  Early 
Reaction b 
Classical 
Reaction c 
Escalating Reactions 
(Phase V) d 
Rashes e 
Phase I 
      A ++ -  + 
 
B +++ +  ++ 
 C ++ -  + 
 D +++ -  - 
 E +++ -  ++ 
Phase V 
a
 
F - - + - 
 G ++ - +++ - 
 H ++ ++ - ++ 
 
a  
 All patients in phase V received 10 mg parenteral chlorpheniramine prior to the first dose of hIgG1-CD4.  
b   Early reaction: - none, + flushing and/ or nausea/ vomiting, ++ flushing and chest tightness, +++    
   flushing and hypotension and/ or chest tightness. 
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c   Classical reaction:   - none, + temperature ↑ 0.5°C and/ or chills, ++ temperature ↑ 0.6-1.5°C and/ or rigor, +++ temperature ↑ >1.6°C and/ or 
hypotension.  
d   Escalating  reactions: - none, + flushing and/ or nausea/ vomiting, ++ flushing and chest tightness,  
  +++ flushing and hypotension and/ or chest tightness or pyrexia > 38.5°C. 
e   Rashes: - none, +localized and settled spontaneously within one week, ++ generalized lasting several  
   weeks. 
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